# US 2012/0251448 A1 · Compounds for Use in the Detection of Neurodegenerative Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251448 A1
- Document ID: US20120251448A1
- Status: Published application
- Kind: A1
- Application number: 13/411,403
- Filed: 2012-03-02
- Published: 2012-10-04
- Earliest claimed: 2011-03-03
- Inventors: Franz F. Hefti; Geoffrey Golding; Ximin Li; Seok-Rye Choi; Luke Esposito; Marisa-Claire Yadon; Joel Cummings; F. Michael Hudson; Thomas Lake; Alan D. Snow
- Web page: https://patentgrep.com/patent/US20120251448A1

## CPC

- A61K 51/0431: {having five-membered rings}
- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of pathological characteristics unique to synuclein diseases, such as Parkinson's disease.

## Claims

### Claim 1

A method of in vivo imaging of α-synuclein aggregates, comprising introducing into a mammal a detectable amount of a compound selected from
which has been labeled with a detectable substance, allowing a sufficient time period for the labeled compound to become associated with α-synuclein aggregates, and detecting the labeled compound associated with one or more α-synuclein aggregates.

### Claim 2 (depends on 1)

The method of claim 1, comprising the additional step of quantifying the amount of labeled compound associated with the one or more α-synuclein aggregates.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of detecting the labeled compound is by positron emission tomography or single photon emission computed tomography.

### Claim 4 (depends on 1)

The method of claim 1, wherein the detectable substance is selected from the group consisting of: radioisotopes, phosphorescent compounds, fluorescent compounds, fluorescent proteins, paramagnetic compounds, metal chelators, and enzymes.

### Claim 5 (depends on 4)

The method of claim 4, wherein the radioisotope is selected from the group consisting of: isotopes of Br, 123I, 125I, 131I, 99mTc, 11C and 18F.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sufficient time period for the labeled compound to become associated with α-synuclein aggregates is from about 5 minutes to a time corresponding to approximately twice the radioactive half-life of the radioisotope of the labeled compound.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sufficient time period for the labeled compound to become associated with α-synuclein aggregates is from about 10 minutes to a time corresponding to the radioactive half-life of the radioisotope of the labeled compound.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sufficient time period for the labeled compound to become associated with α-synuclein aggregates is about 1 to about 60 minutes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the detectable amount of labeled compound comprises from about 0.1 to about 20 mCi.

### Claim 10 (depends on 1)

The method of claim 1, wherein the labeled compound is in dosage form for intravenous injection.

### Claim 11

A kit for detecting α-synuclein aggregates in the brain of an individual, comprising: a labeled compound; and instructions for using the labeled compound, said instructions comprising a direction to administer to an individual a detectable amount of labeled compound; a direction to wait a sufficient period of time; and a direction to detect the labeled compound.
